Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MDMX can interact with MDM2, leading to enhanced MDM2 stabilization and p53 degradation, but the full importance of the MDMX-MDM2 interaction is unclear (Marine et al., 2006; Wade et al., 2010).”
From p53 at a glance (2010) · cites this paper as Marine et al., 2006
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420
Self-citationmdm2 expression is induced by wild type p53 activity.
Barak, Y., Juven, T., Haffner, R., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05678.x · Cited by 1,290
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280
Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265
Self-citationOxygen sensitivity severely limits the replicative lifespan of murine fibroblasts
Parrinello, S., Samper, E., Krtolica, A., Goldstein, J., Melov, S., & Campisi, J. (2003) · Nature Cell Biology · doi:10.1038/ncb1024 · Cited by 1,116
Research works printed but not linked: 3
- Finch RA et al. (2002); 62: 3221–3225.
- Xiang S et al. (2006) Proc. Natl. Acad. Sci. USA. Feb 21 [Epub ahead of print].
- Francoz S et al. (2006) Proc. Natl. Acad. Sci. Feb 21 [Epub ahead of print].
Cited by
Items 101–200 of 365
Wang, C., Wang, J., Liu, Z., Ma, X., Wang, X., Jin, H. D., Zhang, X.-P., Fu, D., Hou, L., & Lu, Y. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu015 · Cited by 64
“Both fulllength MDM4 and MDM2 demonstrated oncogenic potential via inhibition of tumor suppressor p53 (4,5).”
BackgroundKamaraj, B., & Bogaerts, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0134638 · Cited by 64
“The N-terminal region (residues 1–62) contains the transactivation domain, which is further divided into two subdomains, and it is followed by a proline-rich region (residues 63–64), important for apoptotic activity [8, 9].”
BackgroundMcCullagh, E., Seshan, A., El‐Samad, H., & Madhani, H. D. (2010) · Nature Cell Biology · doi:10.1038/ncb2097 · Cited by 62
The p53-mediated cytotoxicity of photodynamic therapy of cancer: Recent advances
Zawacka‐Pankau, J., Krachulec, J., Grulkowski, I., Bielawski, K. P., & Selivanova, G. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2008.07.012 · Cited by 70
Making sense of ubiquitin ligases that regulate p53
Jain, A. K., & Barton, M. C. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.7.13445 · Cited by 66
“MdmX is a well-known example of a regulatory partner that alters Mdm2 activity and even its stability.(30,31) Whether MdmX activity is more or less influential in specific cell types or tissues is unknown and other previously noted modifiers of Mdm2 functions, p300,(37) YY1,(38) Gankyrin,(39) KAP1(40) and Siva1,(41) o…”
BackgroundSmall molecule compounds targeting the p53 pathway: are we finally making progress?
Yu, X., Narayanan, S., Vazquez, A., & Carpizo, D. R. (2014) · Apoptosis · doi:10.1007/s10495-014-0990-3 · Cited by 59
“MDM2 amplifications) or loss of p19 [19, 20].”
p53 Is Positively Regulated by miR-542-3p
Wang, Y., Huang, J., Castellà, M., Huntsman, D. D., & Taniguchi, T. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1706 · Cited by 63
Modifications of p53: competing for the lysines
Carter, S. A., & Vousden, K. H. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.11.010 · Cited by 72
Control of p53 multimerization by Ubc13 is JNK-regulated
Topisirovic, I., Gutierrez, G. J., Chen, M., Appella, E., Borden, K. L. B., & Ronai, Z. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900596106 · Cited by 56
“We have recently shown that Ubc13, an E2 ubiquitin-conjugating enzyme, elicits K63-dependent ubiquitination of p53, which attenuates Hdm2-dependent polyubiquitination and subsequent degradation of p53 (7).”
BackgroundInfluentialProdosmo, A., Giglio, S., Moretti, S., Mancini, F., Barbi, F., Avenia, N., Conza, G. D., Schünemann, H. J., Pistola, L., Ludovini, V., et al. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0322-6 · Cited by 62
Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice
Jung, C., Lim, J. H., Choi, Y., Kim, D., Kang, K. J., Noh, S., & Im, D. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42674 · Cited by 60
Design-rules for stapled peptides with in vivo activity and their application to Mdm2/X antagonists
Chandramohan, A., Josien, H. B., Yuen, T. Y., Duggal, R., Spiegelberg, D., Yan, L. Y., Juang, Y.-C. A., Ge, L., Aronica, P. G. A., Kaan, H. Y. K., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-43346-4 · Cited by 63
Regulation of hematopoietic stem cell fate by the ubiquitin proteasome system
Moran-Crusio, K., Reavie, L., & Aifantis, I. (2012) · Trends in immunology · doi:10.1016/j.it.2012.01.009 · Cited by 54
Regulation of tissue‐ and stimulus‐specific cell fate decisions by p53 in vivo
Jackson, J. G., Post, S. M., & Lozano, G. (2011) · The Journal of Pathology · doi:10.1002/path.2783 · Cited by 53
Self-citationTumor suppression in skin and other tissues via cross-talk between vitamin D- and p53-signaling
Reichrath, J., Reichrath, S., Heyne, K., VOGT, T. M., & Roemer, K. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00166 · Cited by 59
The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death
Chari, N. S., Pinaire, N. L., Thorpe, L., Medeiros, L. J., Routbort, M. J., & McDonnell, T. J. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0327-9 · Cited by 63
“It is widely appreciated the p53-MDM2 interaction is an important determinant of the steady-state levels of p53 protein [155].”
BackgroundTargeting the ubiquitin–proteasome system to activate wild-type p53 for cancer therapy
Allende-Vega, N., & Saville, M. K. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.10.004 · Cited by 52
Targeting TopBP1 at a convergent point of multiple oncogenic pathways for cancer therapy
Chowdhury, P., Lin, G. E., Liu, K., Song, Y., Lin, F., & Lin, W.-C. (2014) · Nature Communications · doi:10.1038/ncomms6476 · Cited by 58
Denisenko, T. V., Pivnyuk, A. D., & Zhivotovsky, B. (2018) · Cancers · doi:10.3390/cancers10050148 · Cited by 54
“The protein also undergoes various posttranslational modifications, which notably affect its activity, and the most prominent negative regulator of p53 is the MDM2 (Mouse double minute 2 homolog) protein [15,16].”
BackgroundNutlins and Ionizing Radiation in Cancer Therapy
Impicciatore, G., Sancilio, S., Miscia, S., & Di Pietro, R. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791033932 · Cited by 49
“Besides MDM2, also MDM4 and its human homolog MDMX bind to p53 with high affinity and effectively inhibit its trans-activation properties but without targeting p53 to degradation [57-59].”
BackgroundInteraction of long noncoding RNA MEG3 with miRNAs: A reciprocal regulation
Moradi, M., Fallahi, H., & Rahimi, Z. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27604 · Cited by 54
“Clinical studies have indicated that TP53 is mutated and functionally inactivated in 50% of cancers.(75,76) Excavation in TarBase (v.”
BackgroundToufektchan, E., Lejour, V., Durand, R., Giri, N., Drašković, I., Bardot, B., Laplante, P., Jaber, S., Alter, B. P., Londoño‐Vallejo, A., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay3511 · Cited by 56
“The phenotypes of Mdm4, p53, p53, p53 and p53 mice were described previously (5,55,56), whereas those of Mdm4, Mdm4 and compound mutants are described in this report.”
Self-citationTargeting the MDM2/MDM4 Interaction Interface as a Promising Approach for p53 Reactivation Therapy
Pellegrino, M., Mancini, F., Lucà, R., Coletti, A., Giacchè, N., Manni, I., Arisi, I., Florenzano, F., Teveroni, E., Buttarelli, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0439 · Cited by 56
“Importantly, these data confirmed previous genetic evidence that optimal p53 reactivation can only be achieved by targeting both MDM proteins simultaneously (16) and therefore highlighted the need of identifying molecules that target both the p53-MDM2 and p53-MDM4 interactions.”
Self-citationCo-expression of Ki-67 and p53 protein in ameloblastoma and keratocystic odontogenic tumor
Gadbail, A. R., Patil, R., & Chaudhary, M. S. (2011) · Acta Odontologica Scandinavica · doi:10.3109/00016357.2011.600714 · Cited by 52
Ovcharenko, D., Stölzel, F., Poitz, D. M., Fierro, F. A., Schaich, M. A., Neubauer, A., Kelnar, K., Davison, T. S., Müller‐Tidow, C., Thiede, C., et al. (2011) · Experimental Hematology · doi:10.1016/j.exphem.2011.07.008 · Cited by 50
Moyer, S. M., Wasylishen, A. R., Qi, Y., Fowlkes, N. W., Su, X., & Lozano, G. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2008474117 · Cited by 48
Self-citationTargeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy
Yi, J., Tavana, O., Li, H., Wang, D., Baer, R. J., & Gu, W. J. (2023) · Nature Communications · doi:10.1038/s41467-023-37617-3 · Cited by 49
Regulation of p53 in embryonic stem cells
Solozobova, V., & Blattner, C. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.06.006 · Cited by 47
“the mouse double minute 2 (Mdm2) protein, which binds to p53 and inhibits several of p53's biochemical activities [9,10].”
BackgroundZinc Metallochaperones as Mutant p53 Reactivators: A New Paradigm in Cancer Therapeutics
Kogan, S., & Carpizo, D. R. (2018) · Cancers · doi:10.3390/cancers10060166 · Cited by 47
“Mdm2 and its homolog Mdmx have been shown to be upregulated in some tumors [20].”
BackgroundA therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)
Skalniak, L., Surmiak, E., & Holak, T. A. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1582645 · Cited by 43
“Therefore, simultaneous targeting of both MDM2 and MDMX may be required for effective anticancer treatment strategies [7,10,11].”
BackgroundSNPs in miRNAs and Target Sequences: Role in Cancer and Diabetes
Chhichholiya, Y., Suryan, A. K., Suman, P., Munshi, A., & Singh, S. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.793523 · Cited by 49
Structural and Functional Comparison of the RING Domains of Two p53 E3 Ligases, Mdm2 and Pirh2
Shloush, J., Vlassov, J. E., Engson, I., Duan, S., Saridakis, V., Dhe-paganon, S., Raught, B., Sheng, Y., & Arrowsmith, C. H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.157669 · Cited by 42
Tissue‐specific and age‐dependent effects of global Mdm2 loss
Zhang, Y., Xiong, S., Li, Q., Hu, S., Tashakori, M., Van Pelt, C., You, M. J., Pageon, L., & Lozano, G. (2014) · The Journal of Pathology · doi:10.1002/path.4368 · Cited by 42
“The Mdm2 E3 ubiquitin ligase mediates ubiquitination of p53 (Trp53) and targets it for degradation [1].”
BackgroundInfluentialSelf-citationThe CXXC finger 5 protein is required for DNA damage-induced p53 activation
Zhang, M., Wang, R., Wang, Y., Diao, F., Lu, F., Gao, D., Chen, D., Zhai, Z., & Shu, H. (2009) · Science in China Series C Life Sciences · doi:10.1007/s11427-009-0083-7 · Cited by 45
MDM2/X inhibitors as radiosensitizers for glioblastoma targeted therapy
Miles, X., Vandevoorde, C., Hunter, A., & Bolcaen, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703442 · Cited by 40
“Hence, studies have shown that combination therapy using MDM2/MDMX inhibitors result in a more effective anti-tumor reaction by more actively inducing apoptosis and cancer cell cycle arrest (81, 101, 104).”
BackgroundFang, S., Krahe, R., Lozano, G., Han, Y., Chen, W., Post, S. M., Zhang, B., Wilson, C. D., Bachinski, L. L., Strong, L. C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010813 · Cited by 43
“While MDM4 inhibits p53 activity in early embryogenesis in animal models, MDM4 has a weak effect on p53 activity in many cell types [14].”
BackgroundSelf-citationZhu, L., Huang, S., Li, J., Chen, J., Yao, Y., Li, L., Guo, H., Xiang, X., Deng, J., & Xiong, J. (2020) · Gene · doi:10.1016/j.gene.2020.144556 · Cited by 40
Synthesis of 5-deazaflavin derivatives and their activation of p53 in cells
Wilson, J. M., Henderson, G., Black, F., Sutherland, A. J., Ludwig, R. L., Vousden, K. H., & Robins, D. J. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.10.011 · Cited by 43
Muttray, A. F., O'Toole, T. F., Morrill, W., Van Beneden, R. J., & Baldwin, S. A. (2010) · Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology · doi:10.1016/j.cbpb.2010.04.008 · Cited by 40
“A second pair-wise multiple alignment with a wider selection of vertebrate MDM2 and MDM4 sequences was performed to identify the MDM gene that we isolated from M. trossulus (Table 1).”
InfluentialDNA-Encoded Macrocyclic Peptide Libraries Enable the Discovery of a Neutral MDM2–p53 Inhibitor
Silvestri, A. P., Zhang, Q., Ping, Y., Muir, E. W., Zhao, J., Chakka, S. K., Wang, G., Bray, W. M., Chen, W., Fribourgh, J. L., et al. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00117 · Cited by 40
Thyroid tumorigenesis and molecular markers in thyroid cancer
Kouniavsky, G., & Zeiger, M. A. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328333846f · Cited by 45
Decision making of the p53 network: Death by integration
Li, Z., Ni, M., Li, J., Zhang, Y., Ouyang, Q., & Tang, C. (2011) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2010.11.041 · Cited by 37
“This non-ubiquitinated p53 will further evade the ubiquitinmediated degradation, the major channel for its destruction (Marine et al., 2006).”
MDM2 and MDMX in Cancer and Development
Marine, J. (2011) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/b978-0-12-380916-2.00003-6 · Cited by 42
Self-citationPATZ1 Is a DNA Damage-Responsive Transcription Factor That Inhibits p53 Function
Keskin, N., Deniz, E., Eryilmaz, J., Ün, M., Batur, T., Erşahin, T., Çetin-Atalay, R., Sakaguchi, S., Ellmeier, W., & Erman, B. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.01475-14 · Cited by 42
“Alternative mechanisms of escape rely on the overexpression of MDM2 and MDMX, major negative regulators of p53 that keep p53 levels low under unstressed conditions through ubiquitination-mediated degradation (3).”
BackgroundCisplatin causes cell death via TAB1 regulation of p53/MDM2/MDMX circuitry
Zhu, Y. Y., Regunath, K., Jacq, X., & Prives, C. L. (2013) · Genes & Development · doi:10.1101/gad.212258.112 · Cited by 40
“Both MDM2 and MDMX are crucial for keeping p53 in check under nonstressed conditions in mice, since deletion of either gene leads to embryonic lethality unless mice also lack functional p53 alleles (Parant et al. 2001; Migliorini et al. 2002; Marine et al. 2006).”
BackgroundSCYL1BP1 modulates neurite outgrowth and regeneration by regulating the Mdm2/p53 pathway
Liu, Y., Chen, Y., Lü, X., Wang, Y., Duan, Y., Cheng, C., & Shen, A. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e12-05-0362 · Cited by 39
“Challenged with stress signals such as hypoxia or DNA damage, the feedback loop of Mdm2-p53 is disturbed, leading to apoptosis or malignancy (Marine et al., 2006).”
Zhang, L., Lu, P., Yan, L., Yang, L., Wang, Y., Chen, J., Dai, J., Li, Y., Kang, Z., Bai, T., et al. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.02.003 · Cited by 39
“Cell cycle progression is partly controlled by CDKs and their activating partners, the cyclins.59 The activation of Cdk1 kinase needs its interacting protein cyclin B to form the maturation-promoting factor, which phosphorylates their respective substrates and controls their functions.60 The p53 protein is a key tumor…”
BackgroundVeerakumarasivam, A., Scott, H. E., Chin, S.-F., Warren, A., Wallard, M. J., Grimmer, D., Ichimura, K., Caldas, C., Collins, V. P., Neal, D. E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4129 · Cited by 36
MDM2- an indispensable player in tumorigenesis
Zafar, A., Khan, M. J., & Naeem, A. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08512-3 · Cited by 41
The p53-Mdm2 Loop: A Critical Juncture of Stress Response
Levav-Cohen, Y., Goldberg, Z., Tan, K. H., Alsheich-Bartok, O., Zuckerman, V., Haupt, S., & Haupt, Y. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_9 · Cited by 42
“genetic studies support the notion that the major physiological importance of Mdm2 relates to its ability to regulate p53 protein abundance and that Mdm2 has little effect on p53 transcriptional activity on a “per molecule” basis (reviewed in [84]).”
BackgroundHypoxia-driven cell motility reflects the interplay between JMY and HIF-1α
Coutts, A. S., Pires, I. M., Weston, L., Buffa, F. M., Milani, M., Li, J., Harris, A. L., Hammond, E. M., & Thangue, N. B. L. (2011) · Oncogene · doi:10.1038/onc.2011.188 · Cited by 41
“The Mdm2 oncoprotein is a key regulator of the p53 response (Marine et al., 2006), and studies identified JMY as a new target through which Mdm2 regulates p53 activity (Coutts et al.”
BackgroundWidespread Overexpression of Epitope-Tagged Mdm4 Does Not Accelerate Tumor Formation In Vivo
De Clercq, S., Gembarska, A., Denecker, G., Maetens, M., Naessens, M., Haigh, K., Haigh, J. J., & Marine, J.-C. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00330-10 · Cited by 35
“activity rather than its stability (28).”
Self-citationHiss, D. C., & Gabriels, G. A. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903052559 · Cited by 37
“Mdm2 or the human homologue of murine double minute 2 is an E3-ubiquitin ligase that binds the transcriptional activation domain of p53 and blocks its ability to regulate target genes and sustain antioncogenic effects, leading to increased and uncontrolled cell proliferation, and malignant transformation [34,72,73].”
BackgroundTorchia, E. C., Chen, Y., Sheng, H., Katayama, H. G., Fitzpatrick, J. A. J., Brinkley, W. R., Caulín, C., Sen, S., & Roop, D. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1059 · Cited by 35
“Mdm2 regulates p53 levels by targeting p53 for ubiquitin-mediated degradation (46).”
BackgroundZhang, Q., He, X., Chen, L., Zhang, C., Gao, X., Yang, Z., & Liu, G. (2012) · The Journal of Pathology · doi:10.1002/path.4077 · Cited by 36
Dolezelova, P., Cetkovska, K., Vousden, K. H., & Uldrijan, S. (2012) · Cell Cycle · doi:10.4161/cc.11.5.19445 · Cited by 32
“Interestingly, while the expression of the p53 inhibitor Mdm2 is stimulated by transcriptionally active p53, thereby forming an autoregulatory feedback loop controlling the cellular levels of both p53 and Mdm2, the MdmX expression is not directly controlled by p53, although Mdm2 expressed in response to p53 activation…”
BackgroundCytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2
Ohtsubo, C., Shiokawa, D., Kodama, M., Gaiddon, C., Nakagama, H., Jochemsen, A. G., Taya, Y., & Okamoto, K. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01180.x · Cited by 32
Are physiological oscillations physiological ?
Xiong, L., & Garfinkel, A. (2023) · The Journal of Physiology · doi:10.1113/jp285015 · Cited by 38
“Moreover, constant high levels of p53 are known to be embryonic lethal (Marine et al., 2006) and can cause widespread tissue damage (Moyer et al.”
BackgroundStochastic Modeling and Simulation of the p53-MDM2/MDMX Loop
Cai, X., & Yuan, Z.-M. (2009) · Journal of Computational Biology · doi:10.1089/cmb.2008.0231 · Cited by 33
“Figure 1 depicts a block diagram of the model for the p53-MDM2/MDMX loop (Toledo and Wahl, 2006; Marine et al., 2006).”
InfluentialIlluzzi, J. L., Vickers, C. A., & Kmiec, E. B. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9516-4 · Cited by 35
“Traditional studies of DNA damage response pathways indicate that p53 becomes active by stabilization through ATM/ATR-mediated phosphorylation, sequence-specific binding, and the transcriptional activation of targeted genes (Marine et al. 2006; Wahl 2006).”
BackgroundInflammation and insulin resistance exert dual effects on adipose tissue tumor protein 53 expression
Ortega, F. J., Moreno‐Navarrete, J. M., Mayas, D., Sérino, M., Rodríguez‐Hermosa, J. I., Ricart, W., Luche, É., Burcelin, R., Tinahones, F. J., Frühbeck, G., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.163 · Cited by 32
Fan, Y., Li, M., Ma, K., Hu, Y., Jing, J., Shi, Y., Li, E., & Dong, D. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1539290 · Cited by 34
“However, targeting the p53-MDM2 interaction merely to reactivate p53 has proved to be insufficient in MDMX overexpressed cancers,(12,13) and optimal p53 reactivation may only be achieved by targeting both MDM proteins simultaneously.(14) Several relevant works focus on dual-target MDM2/MDMX inhibitors recently.”
BackgroundViral-Targeted Strategies Against EBV-Associated Lymphoproliferative Diseases
Hui, K. F., Yiu, S. P. T., Tam, K. P., & Chiang, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00081 · Cited by 31
Therapeutic Efficacy of p53 Restoration in Mdm2 -Overexpressing Tumors
Li, Q., Zhang, Y., El-Naggar, A. K., Xiong, S., Yang, P., Jackson, J. G., Chau, G., & Lozano, G. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0089 · Cited by 30
“Extensive in vitro and in vivo data indicate that Mdm2 negatively regulates p53 function by binding to p53, blocking its transcriptional activity, and functioning as an E3 ubiquitin ligase to ubiquitylate p53 and target it for proteasomal degradation (11).”
BackgroundSelf-citationPuzzling over MDM4–p53 network
Mancini, F., Conza, G. D., Monti, O., Macchiarulo, A., Pellicciari, R., Pontecorvi, A., & Moretti, F. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.04.010 · Cited by 35
MicroRNA-552 links Wnt signaling to p53 tumor suppressor in colorectal cancer
Kwak, B., Kim, D. U., Kim, T. O., Kim, H., & Kim, S. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4505 · Cited by 31
“The tumor suppressor protein, p53, encoded by TP53 , is a key regulator of genomic stability, apoptosis, cell cycle and angiogenesis (10). p53 becomes activated upon various cellular stresses, such as oxidative stress, ribonucleotide depletion, deregulated oncogene expression and DNA damage (11).”
Dissecting the p53-Mdm2 feedback loop in vivo : uncoupling the role in p53 stability and activity
Pant, V., & Lozano, G. (2014) · Oncotarget · doi:10.18632/oncotarget.1797 · Cited by 30
“Since its discovery in the early 90’s, the feedback loop is considered the major pathway necessary for regulating the post-stress levels and activity of p53 in a cell [6, 11-13].”
BackgroundSelf-citationMathematical modelling of p53 basal dynamics and DNA damage response
Chong, K. H., Samarasinghe, S., & Kulasiri, D. (2014) · Mathematical Biosciences · doi:10.1016/j.mbs.2014.10.010 · Cited by 32
Revisiting the Role of p53 in Prostate Cancer
Teroerde, M., Nientiedt, C., Duensing, A. U., Hohenfellner, M., Stenzinger, A., & Duensing, S. M. (2021) · Exon Publications eBooks · doi:10.36255/exonpublications.prostatecancer.p53.2021 · Cited by 38
“MDM2 and MDM4 are co-recruited to these promoters where they form a complex with p53 to modulate target gene activation (34).”
BackgroundTurning the RING Domain Protein MdmX into an Active Ubiquitin-Protein Ligase*
Iyappan, S., Wollscheid, H.-P., Rojas-Fernandez, A., Marquardt, A., Tang, H.-C., Singh, R. K., & Scheffner, M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.115113 · Cited by 25
Macchiarulo, A., Giacchè, N., Carotti, A., Baroni, M., Cruciani, G., & Pellicciari, R. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci800146m · Cited by 33
Mechanisms Underlying Cancer Growth and Apoptosis by DEK Overexpression in Colorectal Cancer
Lin, L., Piao, J., Ma, Y., Jin, T., Quan, C., Kong, J., Li, Y., & Lin, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111260 · Cited by 30
“Challenged with stress signals such as hypoxia or DNA damage, the feedback loop of MDM2-p53 is disturbed, leading to apoptosis or malignancy [33].”
BackgroundTherapeutic Strategies to Activate p53
Aguilar, A., & Wang, S. (2022) · Pharmaceuticals · doi:10.3390/ph16010024 · Cited by 34
“This stabilizes MDM2, resulting in the potentiation of MDM2′s capability for ubiquitination of p53 [94,95].”
BackgroundInfluence of CLOCK on cytotoxicity induced by diethylnitrosamine in mouse primary hepatocytes
Matsunaga, N., Kohno, Y., Kakimoto, K., Hayashi, A., Koyanagi, S., & Ohdo, S. (2010) · Toxicology · doi:10.1016/j.tox.2010.12.005 · Cited by 31
“The 53 tumor suppressor plays a central role in cellular responses to NA damage and other genomic aberrations by inducing cell-cycle rrest, DNA repair, or apoptosis (Marine et al., 2006).”
BackgroundWalter, R. F. H., Mairinger, F. D., Ting, S. C., Vollbrecht, C., Mairinger, T., Theegarten, D., Christoph, D. C., Schmid, K. W., & Wohlschlaeger, J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.27 · Cited by 30
“Overexpression of MDM2 in some tumour types can lead to a loss of P53 regulatory function by increased proteasomal degradation of P53 (Jones et al, 1995; Montes de Oca Luna et al, 1995; Parant et al, 2001; Marine et al, 2006; Ringshausen et al, 2006).”
BackgroundFrom tumor prevention to therapy: Empowering p53 to fight back
Frezza, C., & Martins, C. P. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.10.001 · Cited by 31
“…nevertheless be detected in normal tissues, and in vivo data indicate that such basal levels may be sufficient for the physiologic activity of p53 (Marine et al., 2006). sistan r t W a s t 2 i i d o o u 1 O t p ( g a a M f a n m 2 c a a t o s f c e t I t F r i m m a e t a c a M l p h e p e r c m…”
BackgroundCancer Cells Cue the p53 Response of Cancer-Associated Fibroblasts to Cisplatin
Schmid, J. O., Dong, M., Haubeiß, S., Friedel, G., Bode, S., Grabner, A., Ott, G., Mürdter, T. E., Oren, M., Aulitzky, W. E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1201 · Cited by 32
Jacovas, V. C., Rovaris, D. L., Peréz, O., de Azevedo, S., Macedo, G. S., Sandoval, J. R., Salazar‐Granara, A., Villena, M., Dugoujon, J., Bisso‐Machado, R., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137823 · Cited by 28
Leventaki, V., Rodic, V., Tripp, S. R., Bayerl, M. G., Perkins, S. L., Barnette, P., Schiffman, J. D., & Miles, R. R. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09243.x · Cited by 26
“In addition to genetic lesions affecting TP53, decreased CDKN1A levels could also be related to MDM4 expression because MDM4 can decrease CDKN1A by inhibition of TP53 transcriptional activity (Marine et al, 2006; Liang et al, 2010) or by mediating CDKN1A proteasomal degradation (Jin et al, 2008).”
BackgroundMDMX exerts its oncogenic activity via suppression of retinoblastoma protein
Zhang, H., Hu, L., Qiu, W., Deng, T., Zhang, Y., Bergholz, J. S., & Xiao, Z.-X. (2015) · Oncogene · doi:10.1038/onc.2015.11 · Cited by 28
The Double Role of p53 in Cancer and Autoimmunity and Its Potential as Therapeutic Target
Fierabracci, A., & Pellegrino, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17121975 · Cited by 31
Timmerman, D. M., Remmers, T. L., Hillenius, S., & Looijenga, L. H. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105377 · Cited by 28
“The P53 protein counts 393 amino acids (AA) and consists of multiple domains, starting with a transactivation domain (TAD) at the amino-terminus (N-terminus), a directly neighboring proline-rich domain (PRD), a large DNA-binding domain (DBD), a tetramerization domain (TD), and a carboxy-terminus (C-terminus) regulator…”
BackgroundInfluentialChuang, K., Chiou, S., & Hsu, S. (2023) · Cancers · doi:10.3390/cancers15133338 · Cited by 28
Mdm2 protein Expression is Strongly Associated with Survival in Malignant Pleural Mesothelioma
Mairinger, F. D., Walter, R. F. H., Ting, S. C., Vollbrecht, C., Kollmeier, J., Griff, S., Hager, T., Mairinger, T., Christoph, D. C., Theegarten, D., et al. (2014) · Future Oncology · doi:10.2217/fon.13.261 · Cited by 27
Lam, S., Wiercinska, E., Teunisse, A. F. A. S., Lodder, K., ten Dijke, P., & Jochemsen, A. G. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3147-8 · Cited by 29
“In addition, Mdmx regulates the transcriptional activity of p53 [11, 12].”
BackgroundGeatrell, J. C., Gan, P. M., Mansergh, F. C., Kisiswa, L., Jarrín, M., Williams, L., Evans, M. J., Boulton, M. E., & Wride, M. A. (2009) · Experimental Eye Research · doi:10.1016/j.exer.2009.01.020 · Cited by 26
“Mdm4/X, was not printed on the array used, but is known to be intimately functionally related to both p53 and Mdm2 (Marine et al., 2006).”
BackgroundAnticancer strategies by upregulating p53 through inhibition of its ubiquitination by MDM2
Anifowose, A., Agbowuro, A. A., Yang, X., & Wang, B. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02574-9 · Cited by 30
Montero, E., Abreu, C., & Tonino, P. (2007) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0270-5 · Cited by 26
“The proliferating cell nuclear antigen (PCNA) is a cofactor protein of DNA polymerase delta that plays a major role in DNA synthesis (Linden et al. 1992; Maeda et al. 1999; McLeod and Murray 1999; Capello et al. 2006).”
BackgroundInfluentialBudková, Z., Sigurdardottir, A. K., Briem, E., Bergþorsson, J. Þ., Sigurðsson, S., Magnússon, M. K., Traustadóttir, G. Á., Guðjónsson, Þ., & Hilmarsdóttir, B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00461 · Cited by 26
Roh, J.-L., Kim, E. H., Park, H., & Park, J. Y. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.488 · Cited by 26
“MDMX, a homolog of MDM2, binds to the N-terminal region of p53 or heterodimerizes with MDM2, via C-terminal RING domain interaction, to augment p53 degradation.(8,9) Overexpression”
BackgroundMdm2 exerts pro-apoptotic activities by antagonizing insulin-like growth factor-I-mediated survival
Froment, P., Dupont, J., & Marine, J. (2008) · Cell Cycle · doi:10.4161/cc.7.19.6807 · Cited by 27
Self-citationGuilty as CHARGED: p53's expanding role in disease
Van Nostrand, J. L., & Attardi, L. D. (2014) · Cell Cycle · doi:10.4161/15384101.2014.987627 · Cited by 23
“Subsequent studies using Mdm2 and Mdmx conditional mouse strains further revealed the necessity of regulating p53 in various tissues, including the heart, haematopoietic system, skin, bone, and neuroepithelium, where p53 activation causes increased cell-cycle arrest, senescence or apoptosis and perturbs proper tissue…”
BackgroundGiustiniano, M., Daniele, S., Pelliccia, S., Pietra, V. L., Pietrobono, D., Brancaccio, D., Cosconati, S., Messere, A., Giuntini, S., Cerofolini, L., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00912 · Cited by 25
Liu, Y., Li, C., Liu, H., & Tan, S. (2024) · Archives of Pharmacal Research · doi:10.1007/s12272-024-01494-1 · Cited by 27
“Mouse double minute X (MDMX) binds to the N-terminal region of p53 or heterodimerises with its homologue MDM2 by interacting with its C-terminal domain to augment p53 degradation (Marine et al. 2006).”
Chua, J. S., Liew, H. P., Guo, L., & Lane, D. P. (2015) · Oncogene · doi:10.1038/onc.2015.57 · Cited by 25
Mairinger, F. D., Werner, R., Flom, E., Schmeller, J., Borchert, S., Wessolly, M., Wohlschlaeger, J., Hager, T., Mairinger, T., Kollmeier, J., et al. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2133-z · Cited by 26
Liang, M., Han, X., Vadhan‐Raj, S., Nguyen, M. H., Zhang, Y. H., Fernandez, M., Drakos, E., Konoplev, S. N., Yin, C. C., Miranda, R. N., et al. (2010) · Modern Pathology · doi:10.1038/modpathol.2009.170 · Cited by 27
Crosstalk Between Vitamin D and p53 Signaling in Cancer: An Update
Reichrath, J., Reichrath, S., VOGT, T. M., & Römer, K. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-46227-7_15 · Cited by 27
The roles of mouse double minute 2 (MDM2) oncoprotein in ocular diseases: A review
Jiang, H., Luo, J., & Lei, H. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2021.108910 · Cited by 23
P53 together with ferroptosis: a promising strategy leaving cancer cells without escape
Zhan, J., Wang, J., Liang, Y., Zeng, X., Li, E., & Wang, H. (2023) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023270 · Cited by 23
“After the discovery of a class of cis-imidazoline analogs (nutlins) that inhibit p53-MDM2 binding, MDM2 inhibitors have been widely investigated as targeted therapies for patients with wtp53 [111,112].”
Background
Metadata
- Authors
- Marine, J.-C., Francoz, S., Maetens, M., Wahl, G., Toledo, F., & Lozano, G.
- Affiliations
- Vlaams Instituut voor Biotechnologie (BE)
- Salk Institute for Biological Studies (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Marine, J-C
- Venue
- Cell Death & Differentiation
- Published
- 2006-03-17
- Volume
- 13
- Issue
- 6
- Pages
- 927-934
- ISSN
- 1350-9047 (ISSN-L)
- 1476-5403
- OpenAlex
- W2126832141
- Cited by
- 352
- References
- 27
- Citations by year
- 2026: 9 · 2025: 5 · 2024: 12 · 2023: 12 · 2022: 8 · 2021: 9 · 2020: 16 · 2019: 12 · 2018: 16 · 2017: 16 · 2016: 14 · 2015: 14 · 2014: 26 · 2013: 17 · 2012: 27
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cell Death and Differentiation (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- p53, MDM2, MDM4, p53 regulation, tumor suppressor, DNA damage response, oxidative stress, oncogene activation, mitotic stress, cell cycle arrest, apoptosis, p21, pro-apoptotic genes, p53 target genes
- MeSH terms
- Animals, Antineoplastic Agents, Cell Differentiation, Humans, Neurons, Phenotype, Promoter Regions, Genetic, Protein Processing, Post-Translational, Proto-Oncogene Proteins, Stem Cells, Transcriptional Activation, Tumor Suppressor Protein p53, Apoptosis, Mice, Knockout, Gene Expression Regulation, Developmental, Ubiquitin, Ubiquitin-Protein Ligases, Cell Proliferation, Mice, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.